MedTrace Logo

Impact of Increased Immunoglobulin E to Anti-herpes Simplex Virus -1 Innate Immune Responses in Atopic Dermatitis Patients With Eczema Herpeticum

NCT04060550 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 36

Last updated 2021-03-05

No results posted yet for this study

Summary

This study investigates whether blood monocytes' surface bound- immunoglobulin E affects the innate immune responses against herpes simplex viruses in atopic dermatitis patients with eczema herpeticum.

Conditions

  • Atopic Dermatitis With a History of Eczema Herpeticum
  • Atopic Dermatitis Without a History of Eczema Herpeticum
  • Health Controls Without Atopy

Interventions

BIOLOGICAL

Xolair

This is in vitro mechanistic study. No drug will be given in vivo to patients.

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • National Jewish Health

    lead OTHER

Eligibility

Min Age
16 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-01-09
Primary Completion
2021-07-31
Completion
2021-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04060550 on ClinicalTrials.gov